Opdivo (nivolumab) in combination with Yervoy (ipilimumab) Demonstrates clinical activity
Bristol-Myers Squibb announced new data from a cohort of the phase 2 CheckMate -142 trial evaluating Opdivo (nivolumab) and Yervoy (ipilimumab) for treatment of patients with DNA mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer. January 20, 2018